These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

795 related articles for article (PubMed ID: 25363877)

  • 1. Methodological aspects of minimal residual disease assessment by flow cytometry in acute lymphoblastic leukemia: A French multicenter study.
    Fossat C; Roussel M; Arnoux I; Asnafi V; Brouzes C; Garnache-Ottou F; Jacob MC; Kuhlein E; Macintyre-Davi E; Plesa A; Robillard N; Tkaczuk J; Ifrah N; Dombret H; Béné MC; Baruchel A; Garand R;
    Cytometry B Clin Cytom; 2015 Jan; 88(1):21-9. PubMed ID: 25363877
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Methodological aspects of minimal residual disease assessment by flow cytometry in acute lymphoblastic leukemia: A French multicenter study.
    Fossat C; Roussel M; Arnoux I; Asnafi V; Brouzes C; Garnache-Ottou F; Jacob MC; Kuhlein E; Macintyre-Davi E; Plesa A; Robillard N; Tkaczuk J; Ifrah N; Dombret H; Béné MC; Baruchel A; Garand R;
    Cytometry B Clin Cytom; 2014 Oct; ():. PubMed ID: 25270227
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Flow cytometry and IG/TCR quantitative PCR for minimal residual disease quantitation in acute lymphoblastic leukemia: a French multicenter prospective study on behalf of the FRALLE, EORTC and GRAALL.
    Garand R; Beldjord K; Cavé H; Fossat C; Arnoux I; Asnafi V; Bertrand Y; Boulland ML; Brouzes C; Clappier E; Delabesse E; Fest T; Garnache-Ottou F; Huguet F; Jacob MC; Kuhlein E; Marty-Grès S; Plesa A; Robillard N; Roussel M; Tkaczuk J; Dombret H; Macintyre E; Ifrah N; Béné MC; Baruchel A
    Leukemia; 2013 Feb; 27(2):370-6. PubMed ID: 23070018
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Minimal residual disease analysis in acute lymphoblastic leukemia of childhood within the framework of COALL Study: results of an induction therapy without asparaginase].
    zur Stadt U; Harms DO; Schlüter S; Jorch N; Spaar HJ; Nürnberger W; Völpel S; Gutjahr P; Schrappe M; Janka G; Kabisch H
    Klin Padiatr; 2000; 212(4):169-73. PubMed ID: 10994545
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Major impact of an early bone marrow checkpoint (day 21) for minimal residual disease in flow cytometry in childhood acute lymphoblastic leukemia.
    Eveillard M; Robillard N; Arnoux I; Garand R; Rialland F; Thomas C; Strullu M; Michel G; Béné MC; Fossat C; Loosveld M
    Hematol Oncol; 2017 Jun; 35(2):237-243. PubMed ID: 26449287
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Risk of relapse of childhood acute lymphoblastic leukemia is predicted by flow cytometric measurement of residual disease on day 15 bone marrow.
    Basso G; Veltroni M; Valsecchi MG; Dworzak MN; Ratei R; Silvestri D; Benetello A; Buldini B; Maglia O; Masera G; Conter V; Arico M; Biondi A; Gaipa G
    J Clin Oncol; 2009 Nov; 27(31):5168-74. PubMed ID: 19805690
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical importance of minimal residual disease in childhood acute lymphoblastic leukemia.
    Coustan-Smith E; Sancho J; Hancock ML; Boyett JM; Behm FG; Raimondi SC; Sandlund JT; Rivera GK; Rubnitz JE; Ribeiro RC; Pui CH; Campana D
    Blood; 2000 Oct; 96(8):2691-6. PubMed ID: 11023499
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lineage classification of childhood acute lymphoblastic leukemia according to the EGIL recommendations: results of the ALL-BFM 2000 trial.
    Ratei R; Schabath R; Karawajew L; Zimmermann M; Möricke A; Schrappe M; Ludwig WD
    Klin Padiatr; 2013 May; 225 Suppl 1():S34-9. PubMed ID: 23700065
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Early (Day 15 Post Diagnosis) Peripheral Blood Assessment of Measurable Residual Disease in Flow Cytometry is a Strong Predictor of Outcome in Childhood B-Lineage Lymphoblastic Leukemia.
    Loosveld M; Nivaggioni V; Arnoux I; Bernot D; Michel G; Béné MC; Eveillard M
    Cytometry B Clin Cytom; 2019 Mar; 96(2):128-133. PubMed ID: 30734503
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Minimal residual disease assessment in childhood acute lymphoblastic leukaemia: a Swedish multi-centre study comparing real-time polymerase chain reaction and multicolour flow cytometry.
    Thörn I; Forestier E; Botling J; Thuresson B; Wasslavik C; Björklund E; Li A; Lindström-Eriksson E; Malec M; Grönlund E; Torikka K; Heldrup J; Abrahamsson J; Behrendtz M; Söderhäll S; Jacobsson S; Olofsson T; Porwit A; Lönnerholm G; Rosenquist R; Sundström C
    Br J Haematol; 2011 Mar; 152(6):743-53. PubMed ID: 21250970
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Minimal residual disease assessed by multi-parameter flow cytometry is highly prognostic in adult patients with acute lymphoblastic leukaemia.
    Ravandi F; Jorgensen JL; O'Brien SM; Jabbour E; Thomas DA; Borthakur G; Garris R; Huang X; Garcia-Manero G; Burger JA; Ferrajoli A; Wierda W; Kadia T; Jain N; Wang SA; Konoplev S; Kebriaei P; Champlin RE; McCue D; Estrov Z; Cortes JE; Kantarjian HM
    Br J Haematol; 2016 Feb; 172(3):392-400. PubMed ID: 26492205
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Treatment outcome of childhood standard-risk and median-risk acute lymphoblastic leukemia with CCLG-2008 protocol].
    Liu X; Zou Y; Wang H; Chen X; Ruan M; Chen Y; Yang W; Guo Y; Liu T; Zhang L; Wang S; Zhang J; Liu F; Cai X; Qi B; Chang L; Zhu X
    Zhonghua Er Ke Za Zhi; 2014 Jun; 52(6):449-54. PubMed ID: 25190166
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Flow-cytometric minimal residual disease monitoring in blood predicts relapse risk in pediatric B-cell precursor acute lymphoblastic leukemia in trial AIEOP-BFM-ALL 2000.
    Schumich A; Maurer-Granofszky M; Attarbaschi A; Pötschger U; Buldini B; Gaipa G; Karawajew L; Printz D; Ratei R; Conter V; Schrappe M; Mann G; Basso G; Dworzak MN;
    Pediatr Blood Cancer; 2019 May; 66(5):e27590. PubMed ID: 30561169
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Monitoring of minimal residual disease in children with acute lymphoblastic leukemia and its prognostic significance].
    Xu XJ; Tang YM; Song H; Shi SW; Yang SL; Shen HQ; Wei J; Xu WQ; Pan BH; Zhao FY
    Zhonghua Er Ke Za Zhi; 2010 Mar; 48(3):180-4. PubMed ID: 20426951
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Flow cytometric follow-up of minimal residual disease in bone marrow gives prognostic information in children with acute lymphoblastic leukemia.
    Björklund E; Mazur J; Söderhäll S; Porwit-MacDonald A
    Leukemia; 2003 Jan; 17(1):138-48. PubMed ID: 12529671
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Monitoring of minimal residual disease in acute leukemia by multiparametric flow cytometry.
    Kusenda J; Fajtova M; Kovarikova A
    Neoplasma; 2014; 61(2):119-27. PubMed ID: 24299307
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Detection of minimal residual disease in pediatric acute lymphoblastic leukemia.
    Gaipa G; Basso G; Biondi A; Campana D
    Cytometry B Clin Cytom; 2013; 84(6):359-69. PubMed ID: 23757107
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Minimal residual disease levels in bone marrow and peripheral blood are comparable in children with T cell acute lymphoblastic leukemia (ALL), but not in precursor-B-ALL.
    van der Velden VH; Jacobs DC; Wijkhuijs AJ; Comans-Bitter WM; Willemse MJ; Hählen K; Kamps WA; van Wering ER; van Dongen JJ
    Leukemia; 2002 Aug; 16(8):1432-6. PubMed ID: 12145681
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Status of minimal residual disease after induction predicts outcome in both standard and high-risk Ph-negative adult acute lymphoblastic leukaemia. The Polish Adult Leukemia Group ALL 4-2002 MRD Study.
    Holowiecki J; Krawczyk-Kulis M; Giebel S; Jagoda K; Stella-Holowiecka B; Piatkowska-Jakubas B; Paluszewska M; Seferynska I; Lewandowski K; Kielbinski M; Czyz A; Balana-Nowak A; Król M; Skotnicki AB; Jedrzejczak WW; Warzocha K; Lange A; Hellmann A
    Br J Haematol; 2008 Jun; 142(2):227-37. PubMed ID: 18492099
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Minimal residual disease monitoring cannot fully replace bone marrow morphology in assessing disease status in pediatric acute lymphoblastic leukemia.
    Rathe M; Preiss B; Marquart HV; Schmiegelow K; Wehner PS
    APMIS; 2020 May; 128(5):414-419. PubMed ID: 32108963
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 40.